Table 3. Ultrasonic and clinical results of MPFF treatment in 24 patients with VSPV.
| Characteristics of patients in the MPFF group (N = 24) | Before treatment | After treatment | p-Value | |||
|---|---|---|---|---|---|---|
| Ultrasonic results | ||||||
| Place of dilated VSPV, N (%) | ||||||
| Left side | Unilateral | 11 (46) | 14 (58) | 12 (50) | 16 (67) | 0.0371 |
| Right side | 3 (12) | 4 (17) | ||||
| Bilateral | 10 (42) | 2 (8) | ||||
| No dilation | 0 | 6 (25) | ||||
| Degree of dilation, N (%) | ||||||
| Grade 1 | 2 (10) | 7 (29) | 0.0863 | |||
| Grade 2 | 19 (80) | 11 (46) | ||||
| Grade 3 | 2 (10) | 0 (0) | ||||
| No dilation | 0 | 6 (25) | ||||
| Mean diameter, mm (95% CI) | 7.59 (5.04–9.70) | 5.92 (3.40–8.27) | 0.0001 | |||
| Retrograde blood flow, N (%) | 16 (67) | 4 (17) | 0.0220 | |||
| Clinical results | ||||||
| Impaired urination | 24 (100) | 9 (37) | 0.0310 | |||
| Pelvic pain | 8 (33) | 1 (4) | 0.0408 | |||
| Dyspareunia (women) | 3 (43) | 1 (14) | NS | |||
Abbreviations: CI, confidence interval; MPFF, micronized purified flavonoid fraction; VSPV, varicose small pelvic veins.